Triple-drug attack aims to shrink tough skin cancers before surgery
NCT ID NCT07501104
First seen Apr 13, 2026 · Last updated Apr 23, 2026 · Updated 2 times
Summary
This study tests whether giving three drugs (pucotenlimab, lenvatinib, and temozolomide) before surgery can shrink stage IIB/III acral melanoma, a type of skin cancer on the palms, soles, or under nails. About 30 adults will receive the combination for three 3-week cycles, then have surgery. After surgery, those whose tumors didn't shrink enough will continue one drug for a year. The goal is to see how many patients have a major response in their tumor tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA (SKIN CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.